Feb 7, 2017, 1pm EST
The HPTN has launched HPTN 083, the first large-scale study to test efficacy and safety of injectable cabotegravir (CAB) for pre-exposure prophylaxis (PrEP). You are invited to register for our upcoming webinar to learn more about HPTN 083.
HPTN 083 will evaluate whether injectable cabotegravir (CAB) can safely protect cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as Truvada, an oral tablet taken daily for HIV prevention, also known as pre-exposure prophylaxis (PrEP). If found to be safe and effective for HIV PrEP, injectable CAB may be easier for some people to adhere to than daily oral Truvada.
This webinar will provide a comprehensive overview of HPTN 083 by explaining why the study is being done and what will happen during the study. Additionally, the HPTN’s commitment to community participation at all levels of research will be described by detailing the many community involvement and engagement activities used in preparation for the study and now during its implementation.